Kancera prepares for clinical development
Niclas Brynne (born 1961) holds a Ph.D. in Medical Sciences, Clinical Pharmacology. He has more than 25 years of experience from clinical development positions at Pharmacia and AstraZeneca. In these companies, Niclas has been responsible for progressing new discoveries from preclinical research through clinical development to marketed drugs. Most recently Niclas comes from a position as Senior VP, Head Clinical Projects, at Mentiscura Diagnostics.
"Kancera has developed a portfolio of preclinical drug projects against cancer diseases that cannot be cured with existing therapies. The next step in Kancera’s development is to test selected candidate drugs in humans. We are therefore pleased to welcome Niclas Brynne, who provides a broad knowledge and extensive experience of clinical development of new treatment concepts”, says Thomas Olin, CEO of Kancera AB.
About Kancera AB
Kancera develops the basis for new therapeutics, starting with new treatment concepts and ending with the sale of a drug candidate to international pharmaceutical companies. Kancera is currently developing drugs for the treatment of leukemia and solid tumors, based on blocking survival signals in the cancer cell and on addressing cancer metabolism. Kancera’s operations are based in the Karolinska Institutet Science Park in Stockholm and the company employs around 15 people. Kancera shares are traded on NASDAQ First North and the number of shareholders with more than 500 shares were 7700 as of July, 2016. FNCA is Kancera’s Certified Adviser. Professor Carl-Henrik Heldin, Professor Håkan Mellstedt, and MD PhD Charlotte Edenius are board members and Kancera´s scientific advisers.
For further information, please contact,
Thomas Olin, CEO: +46 (0) 735 20 40 01
Kancera AB (publ)
Karolinska Institutet Science Park,
SE 171 48 Solna
Please visit the company website; http://www.kancera.comBack